Novo Nordisk sees good potential for Victoza in Japan
This article was originally published in Scrip
Executive Summary
Novo Nordisk has high hopes for its new diabetes product Victoza (liraglutide) in Japan, despite the GLP-1 agonist being administered by injection rather than orally.